Some Peculiarities of Modern Comorbid Tuberculosis Therapy

The aim of the work was to study the effectiveness of remaxol inclusion in treatment regimens designed for patients with comorbid tuberculosis and hepatotoxic response to etiotropic therapy.

Materials and Methods. Case histories of 25 patients (21 men and 4 women) with a confirmed diagnosis of tuberculosis infection and hepatotoxic reactions to etiotropic treatment were analyzed. Of these, 9 patients had a comorbid (TB/HIV) pathology and 16 patients had TB/HIV with concomitant diseases. To stop the signs of hepatotoxicity, all patients were prescribed with remaxol: 400 ml intravenously on alternate days (course No. 5), then 1 time per week (course No. 4). In addition to the standard clinical and laboratory examination, all patients underwent follow-up (before and after the course of remaxol) examination of the levels of aspartate aminotransferase and total bilirubin in the blood, as well as the levels of interleukin production (1β, 4, 6 and 10) and tumor necrosis factors (TNF-α and TNF-γ). Standard regimens were used when conducting anti-tuberculosis chemotherapy.

Results. It was noted that the presence of a comorbidity aggravates the course of tuberculosis and reduces the effectiveness of etiotropic therapy due to the development of hepatotoxicity. The inclusion of remaxol contributed to a decrease in the severity of hepatotoxic reactions and made it possible to avoid the correction of the main treatment course. The revealed positive dynamic in cytokine profile indicators can be regarded as a mediated immunological effect of the drug and requires further research.

1. Global tuberculosis report 2021. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

2. Baryshnikova L. A., Kabaeva M. N., Voekova N. A., Loginova N. A., Sirotko I. I. Organizatsiya deyatel'nosti protivotuberkuleznykh meditsinskikh uchrezhdenij v usloviyakh pandemii COVID-19. Tuberkulez I Bolezni Legkikh. 2021; 99 (3): 12–17. http://doi.org/10.21292/2075-1230-2021-99-3-12-1. (in Russian)

3. Lebedeva I.B., Osintseva I.Jyu., Bondarenko T.E., P'yanzova T.V., Brusina E.B. COVID-19 v populyatsii bol'nykh tuberkulezom: epidemiologicheskaya i klinicheskaya kharakteristiki. Fundamental'naya i Klinicheskaya Meditsina. 2021; 6 (3): 71–84. https://doi.org/10.23946/2500-0764-2021-6-3-71-84. (in Russian)

4. Savintseva E. V., Isaeva P. V., Nizamov G. F. Tuberkulez I COVID-19: meditsinskie I sotsial'nye aspekty. Tuberkulez I Bolezni Legkikh 2022; 100 (3): 13–17. http://doi.org/10.21292/2075-1230-2022-100-3-13-17. (in Russian)

5. Sterlikov S.A., Son I.M., Saenko S.S., Rusakova L.I., Galkin V.B. Vozmozhnoe vliyanie pandemii COVID-19 na epidemicheskujyu situatsijyu po tuberkulezu. Sovremennye Problemy Zdravookhraneniya i Meditsinskoj Statistiki. 2020; 2: 191–205. https://doi.org/24411/2312-2935-2020-00042. (in Russian)

6. Kolpakova T.A. Problema Komorbidnosti v Klinike Legochnogo Tuberkulez. Bjyulleten' VSNTs SO RAMN. 2011; 2 (78): 48–51. (in Russian)

7. Yablonskij P.K., Starshinova A.A., Nazarenko M.M., Belyaeva E.N., Chuzhov A.L., Alekseev D. Jyu. Pavlova M.V. Effektivnost' lecheniya tuberkuleza s lekarstvennoj ustojchivost'jyu vozbuditelya u bol'nykh s razlichnym komorbidnym statusom. Meditsinskij Al'yans. 2022; 10 (1): 6–15. https://doi.org/10.36422/23076348-2022-10-1-6-15. (in Russian)

8. Katicheva A.V., Brazhenko N.A., Brazhenko O.N., Zheleznyak S.G., Tsygan N.V. Tuberkulez organov dykhaniya, assotsiirovannyj s khronicheskoj obstruktivnoj bolezn'jyu legkikh, –aktual'naya problema ftiziatrii. Vestnik Rossijskoj Voenno-Meditsinskoj Akademii. 2020; 1 (69): 185–190. (in Russian)

9. Azovtseva O.V., Gritsjyuk A.V., Gemaeva M.D., Karpov A.V., Arkhipov G.S. VICh-infektsiya i tuberkulez kak naibolee slozhnyj variant komorbidnosti. Vestnik Novgorodskogo Gosudarstvennogo Universiteta. 2020; 1 (117): 79–84. https://doi.org/10.34680/2076-8052.2020.1(117).79-84. (in Russian)

10. Balasanyants G.S. Gepatotoksicheskie reaktsii i gepatoprotektivnaya terapiya vo ftiziatrii. Tuberkulez i Bolezni Legkikh. 2015; 8: 48–52. (in Russian)

11. Il'chenko L.Jyu., Okovityj S.V. Remaksol: mekhanizmy dejstviya i primenenie v klinicheskoj praktik. Arkhiv Vnutrennej Meditsiny. Spetsial'nyj Vypusk. 2016; 1–14. (in Russian)

12. Volchegorskij I.A., Novoselov P.N., Ushkareva E.V. Vliyanie remaksola na effektivnost' standartnogo lecheniya bol'nykh infil'trativnym tuberkulezom legkikh Terapevticheskij Arkhiv. 2016; 3: 73–78. (in Russian)

13. Shurygin A.A., Alekseeva Jyu.A. Effektivnost' primeneniya remaksola v terapii porazhenij pecheni, vyzvannykh priemom protivotuberkuleznykh preparatov. Ftiziatriya i Pul'monologiya. 2016; 1: 51–53. (in Russian)

14. Vasil'eva I.A, Voronin E.E., Pokrovskij V.V. i dr. Federal'nye klinicheskie rekomendatsii po profilaktike, diagnostike i lechenijyu tuberkuleza u bol'nykh VICh-infektsiej. Moscow: Rossijskoj Obshchestvo Ftiziatrov, 2016; 42. (in Russian)